Mekki Sahar*, Damak Chifa, Frikha Faten, Mouna Snoussi, Raida Ben Salah, Yosra Bouattour, Sameh Marzouk and Zouhir Bahloul

Internal Medicine Department of the Hedi Chaker University Hospital, Sfax Medical School, Sfax, Tunisia

*Corresponding Author: Mekki Sahar, Internal Medicine Department of the Hedi Chaker University Hospital, Sfax Medical School, Sfax, Tunisia.

Received: November 30, 2021; Published: January 12, 2022

Abstract

Purpura are red-brown lesions caused by localized haemorrhage into the skin. Vascular causes of purpura may be the result of inflammation, vascular fragility, or microvascular occlusion leading to local ischaemia, and it is most commonly associated with small vessel disease affecting the superficial vessels of the dermis.

This article provides the experience of an internal medicine department about purpura with vascular causes.

Case Presentation: It was a retrospective study including 73 patients with palpable purpura hospitalized in the internal medicine department of the Hedi Chaker University Hospital of Sfax during the period between 1996 and 2020.

Our population consisted of 27 men (36.9%) and 46 women (63%). The average age of the patients was 43.7 years with extremes ranging from 14 to 90 years. Systemic diseases were the most frequent aetiology, found in 26 cases (35.6%), Henoch-Schoenlein purpura (HSP) was the most frequent systemic disease found (16 cases), 7 patients were diagnosed with Sjögren's syndrome (SS). Other autoimmune diseases were found: systemic lupus erythematosus (2 cases), eosinophilic granulomatosis with polyangiitis (1 case).

An infectious cause was found in 12 cases (16.4%): hepatitis (7 cases), post streptococcal (2 cases), post-meningococcal (1 case), cytomegalovirus infection (1 case) and parvovirus B19 (1 case). In 20 cases (27.4%), the aetiology of purpura was unknown. 

Skin biopsies were performed in 49 patients, showed leukocytoclastic vasculitis in 32 cases (43.8%).

In terms of therapy, bed rest was recommended for all patients. Colchicine was prescribed in 6 cases. Corticosteroid therapy was prescribed in 20 patients, associated in 3 cases with immunosuppressive treatment. The evolution of PV was favorable in the majority of cases with regression of lesions in 47 cases (64.3%).

Keywords: Tetanus; WHO Guideline; Vaccine; Iraq; Kurdistan

References

1. Kawakami T., et al. “New algorithm (KAWAKAMI algorithm) to diagnose primary cutaneous vasculitis”. Journal of Dermatology2 (2010): 113-124.
2. Katsambas A., et al. “Life-threatening purpura and vasculitis”. Clinics in Dermatology 23 (2005): 227-237.
3. A Mtira., et al. “Les purpuras vasculaires: profil étiologique de 101 cas”. La Revue de Médecine Interne 42 (2021): A95-A206.
4. MS Hamdi., et al. “Purpura vasculaire: une enquête étiologique s’impose!”. La Revue de Médecine Interne 35S (2014): A96-A200.
5. Liv Eline H., et al. “Henoch-Schönlein Purpura: A Literature Review”. Acta Dermato-Venereologica10 (2017): 1160-1166.
6. Ashley K., et al. “Dermatologic Manifestations of Sjögren Syndrome”. Journal of Cutaneous Medicine and Surgery 15 (2011): 8-14.
7. SC Charrot ., et al. “Purpura”. British Journal of Hospital Medicine 10 (2017).

Citation

Citation: Mekki Sahar., et al. “Vascular Purpura: A Cohort Study of 73 Patients”.Acta Scientific Medical Sciences 6.2 (2022): 58-60.

Copyright

Copyright: © 2022 Mekki Sahar., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.